We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-11.64%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$782M
AUM Growth
-$228M
Cap. Flow
+$27.9M
Cap. Flow %
3.57%
Top 10 Hldgs %
64.89%
Holding
44
New
7
Increased
12
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$40.7M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$29.8M
3
ACOR
Acorda Therapeutics
ACOR
+$17.2M
4
ARDX icon
Ardelyx
ARDX
+$17M
5
TGTX icon
TG Therapeutics
TGTX
+$15M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$102M
2
RGLS
Regulus Therapeutics
RGLS
+$16.2M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$14.8M
4
BPMC
Blueprint Medicines
BPMC
+$14.3M
5
COLL icon
Collegium Pharmaceutical
COLL
+$6.75M

Sector Composition

Rank Sector Weight
1 Healthcare 91.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
26
BioCryst Pharmaceuticals
BCRX
$2.35B
$8.46M 1.08%
2,989,795
-104,269
-3% -$462K
NTRA icon
27
Natera
NTRA
$38.6B
$7.46M 0.95%
783,520
– –
RGLS
28
DELISTED
Regulus Therapeutics
RGLS
$7.24M 0.93%
8,709
-20,315
-70% -$16.2M
AGRX
29
DELISTED
Agile Therapeutics
AGRX
$6.61M 0.84%
+532
New +$6.87M
ONC
30
BeOne Medicines Ltd
ONC
$33.4B
$4.98M 0.64%
+170,000
New +$4.82M
TENX icon
31
Tenax Therapeutics
TENX
$401M
$4.9M 0.63%
75
– –
EIGR
32
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.89M 0.63%
+9,723
New +$4.84M
ZYNE
33
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$4.79M 0.61%
507,191
– –
SRRA
34
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.08M 0.52%
15,125
– –
AGTC
35
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3.3M 0.42%
236,059
– –
ORKA
36
Oruka Therapeutics
ORKA
$5.9B
$2.7M 0.35%
3,603
– –
AKTX
37
Akari Therapeutics
AKTX
$14M
$2.6M 0.33%
322
-8
-2% -$82.9K
ALPN
38
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.56M 0.33%
153,216
– –
NDRM
39
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.04M 0.26%
144,671
– –
BPMC
40
DELISTED
Blueprint Medicines
BPMC
$1.02M 0.13%
56,442
-821,906
-94% -$14.3M
DSCI
41
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$252K 0.03%
81,239
-559,997
-87% -$1.88M
ARMP icon
42
Armata Pharmaceuticals
ARMP
$175M
$211K 0.03%
383
– –
GBT
43
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-457,142
Closed -$14.8M
DYAX
44
DELISTED
DYAX CORPORATION
DYAX
– –
-2,717,618
Closed -$102M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, RA Capital Management held 44 positions worth $782M, down 23% from $1.01B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

RA Capital Management deployed $27.9M of net new capital in Q1 2016, opening 7 new positions and adding to 12 existing holdings. Its largest new stake was Nektar Therapeutics: 211,924 shares worth $43.7M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 85% a quarter earlier.

On the sell side, the largest reduction was Regulus Therapeutics, an estimated $16.2M trimmed.

  • RA Capital Management's largest Q1 2016 buy was Nektar Therapeutics: 211,924 shares worth $43.7M.
  • RA Capital Management added most to Ardelyx in Q1 2016, an estimated $17M increase.
  • RA Capital Management's biggest Q1 2016 reduction was Regulus Therapeutics, cutting an estimated $16.2M.
  • RA Capital Management fully exited DYAX CORPORATION in Q1 2016, selling an estimated $102M.
  • RA Capital Management's ten largest holdings make up 65% of its $782M portfolio in Q1 2016.
  • RA Capital Management opened 7 new positions and closed 2 in Q1 2016.
  • RA Capital Management's portfolio value fell 23% quarter-over-quarter to $782M.

Based on RA Capital Management's 13F filing for Q1 2016, filed 16 May 2016.